[go: up one dir, main page]

CN112870155B - Gel injection of sustained release dexamethasone medicine, preparation method and application thereof - Google Patents

Gel injection of sustained release dexamethasone medicine, preparation method and application thereof Download PDF

Info

Publication number
CN112870155B
CN112870155B CN202110251929.1A CN202110251929A CN112870155B CN 112870155 B CN112870155 B CN 112870155B CN 202110251929 A CN202110251929 A CN 202110251929A CN 112870155 B CN112870155 B CN 112870155B
Authority
CN
China
Prior art keywords
dexamethasone
gel
medicine
drug
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110251929.1A
Other languages
Chinese (zh)
Other versions
CN112870155A (en
Inventor
顾也欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yuju Technology Co ltd
Original Assignee
Shanghai Yuju Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yuju Technology Co ltd filed Critical Shanghai Yuju Technology Co ltd
Priority to CN202110251929.1A priority Critical patent/CN112870155B/en
Publication of CN112870155A publication Critical patent/CN112870155A/en
Application granted granted Critical
Publication of CN112870155B publication Critical patent/CN112870155B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the technical field of medical medicaments, and discloses a gel injection for slowly releasing dexamethasone medicaments, which comprises dexamethasone medicaments and gel particles, wherein the dexamethasone medicaments are entrapped in the gel particles, and the medicament molecules which are partially soluble and dissolved have hydrogen bond interaction with gel network molecules so as to slowly release the medicaments; according to the invention, the dexamethasone medicine is loaded into the crosslinked polyacrylamide gel particles under specific conditions, and the long-acting slow release of the dexamethasone medicine is realized by virtue of partial dissolution of the dexamethasone medicine by the gel particles and hydrogen bond interaction between gel network molecules and the medicine, so that the gel injection for slowly releasing the dexamethasone medicine is invented.

Description

Gel injection of sustained release dexamethasone medicine, preparation method and application thereof
Technical Field
The invention relates to the technical field of medical medicaments, in particular to a gel injection of a sustained release dexamethasone medicament, and a preparation method and application thereof, which play a role in relieving acute inflammation, synovitis and rheumatic/rheumatoid arthritis in a short term and simultaneously play a role in joint lubrication and joint injury repair in a long term.
Background
Joint pathologies such as synovitis, joint injuries, arthritis are often localized lesions, and the treatment of local administration of anti-inflammatory agents by intra-articular injection may reduce side effects associated with systemic administration.
Dexamethasone is an adrenocortical hormone anti-inflammatory agent, has strong anti-inflammatory and immunosuppressive effects, has general application in the treatment of acute and chronic inflammation, can be clinically applied by local smearing, oral administration or intravenous or intramuscular injection, and is used for treating acute inflammation, synovitis and rheumatic/rheumatoid arthritis of joint injury. However, the dosage and the course of treatment of dexamethasone are strictly controlled, and the large dosage can cause serious side effects such as femoral head necrosis, osteoporosis, cushing's syndrome, muscular atrophy, gastrointestinal dysfunction and the like after long-term use. The dexamethasone drugs used in clinical treatment at present mainly comprise water-soluble dexamethasone phosphate, water-insoluble dexamethasone and dexamethasone acetate, the retention time of the drugs in vivo is short after injection, for example, the plasma half-life of the dexamethasone after absorption through the alimentary canal is only 190 minutes, the tissue half-life of the dexamethasone after injection administration is only 72 hours, the dexamethasone has good curative effect after multiple administration, and frequent intra-articular cavity injection administration brings pain to patients, and systemic toxic and side effects caused by the local injection of the drugs entering blood circulation are also caused, so that the application is limited.
The crosslinked polyacrylamide gel has good biocompatibility, and can be processed into gel particles for injection into joint cavities to play a role in lubrication and buffering, and the composition and cytokines of synovial cells can be changed, so that the crosslinked polyacrylamide gel can be used for treating diseases such as synovitis, osteoarthritis and the like. However, the gel alone does not have the functions of anti-inflammatory and immunity inhibition, and particularly cannot play the roles of rapid detumescence and anti-inflammatory in some acute joint inflammations.
According to the invention, the dexamethasone medicine is loaded into the crosslinked polyacrylamide gel particles under specific conditions, and the long-acting slow release of the dexamethasone medicine is realized by virtue of partial dissolution of the dexamethasone medicine by the gel particles and hydrogen bond interaction between gel network molecules and the medicine, so that the gel injection for slowly releasing the dexamethasone medicine is invented.
Disclosure of Invention
(one) solving the technical problems
Aiming at the defects of the prior art, the invention provides a gel injection for slowly releasing dexamethasone medicine, a preparation method and application thereof, has the advantage of rapid anti-inflammatory and detumescence, and solves the problem of no anti-inflammatory and immunity-inhibiting effects.
(II) technical scheme
In order to achieve the above purpose, the present invention provides the following technical solutions: the gel injection for slowly releasing the dexamethasone medicine comprises the dexamethasone medicine and gel particles, wherein the dexamethasone medicine is entrapped in the gel particles, and the medicine molecules after the medicine is partially soluble and the dissolved medicine molecules have hydrogen bond interactions with gel network molecules, so that the medicine can be slowly released.
Preferably, the dexamethasone drug is one or a combination of several of dexamethasone, dexamethasone sodium phosphate and dexamethasone acetate, and the loading amount of the drug in the gel particles is 0.01% -1%.
Preferably, the particle size of the gel particles is 0.5-1000 mu m, and the gel particles consist of crosslinked polyacrylamide, salt and water for injection, wherein the content of the crosslinked polyacrylamide is 0.01-5%; the salt content is 0.001% -5%, and the balance is water, glycerol or a mixed solution of water and glycerol.
Preferably, the crosslinking degree of the crosslinked polyacrylamide is 0.1% -99%, the molecular weight of the polyacrylamide is 1x104-1x106, and the molecular weight distribution coefficient is 1-5.
Preferably, the salt comprises one or a combination of several of sodium chloride, potassium chloride, zinc chloride, calcium chloride, magnesium chloride, zinc acetate, disodium hydrogen phosphate and monopotassium phosphate.
Preferably, the dexamethasone drug can be controlled to be released, and the controlled release period of the drug is 0.1h-30d.
Preferably, the injection can be performed by various types of syringes in clinical practice.
The gel injection for slowly releasing dexamethasone medicine and its preparation process includes the following steps:
s1: processing the crosslinked polyacrylamide into micron particles;
s2: dissolving dexamethasone in one or more of water, ethanol and salt solution;
s3: mixing the liquid obtained in the step S2 with the powder obtained in the step S1 in proportion, and treating for 0.1-72h at 4-80 ℃ by adopting one or a combination of more of vibration, standing, stirring and ultrasound to obtain medicine carrying gel;
s4: and (3) removing or partially removing the solvent from the drug-loaded gel obtained in the step (S3) in a heating and/or vacuumizing and evaporation accelerating mode, adding a proper amount of water or salt solution in proportion, standing for 0.1-72h, and sterilizing to obtain the gel injection for slowly releasing the dexamethasone drug.
Preferably, the processing method of the crosslinked polyacrylamide into particles comprises one or a combination of grinding, freeze-crushing and ultrasonic crushing.
Preferably, the method comprises the steps of,
1. the dexamethasone medicine is slowly released in a short period to relieve and treat acute inflammation, synovitis and rheumatic/rheumatoid arthritis;
2. long-term intra-articular retention through the crosslinked polyacrylamide plays a role in joint lubrication, joint injury repair and synovitis and arthritis treatment.
(III) beneficial effects
Compared with the prior art, the invention provides the gel injection for slowly releasing the dexamethasone drug, and the preparation method and the application thereof, and has the following beneficial effects:
the invention has the beneficial effects that the gel injection can rapidly release dexamethasone medicine at the initial stage, plays a role in rapidly resisting inflammation and diminishing swelling, gradually slows down the release of medicine at the later stage, slowly stops administration, avoids adverse side effects caused by sudden stopping of administration, can maintain the gel after injection for 1-2 years locally, plays a role in lubrication and buffering for a long time, and can realize the continuous therapeutic effect of one-time joint cavity injection for many years.
Drawings
FIG. 1 shows a gel injection D1 of the dexamethasone slow release drug of example 1.
FIG. 2 shows the sustained release of dexamethasone by gel injection D2, which is the sustained release dexamethasone drug in example 2.
FIG. 3 is a gel injection D3 of the dexamethasone slow release drug of example 4
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
The gel injection D1 for slowly releasing the dexamethasone medicine comprises dexamethasone sodium phosphate with the content of 0.1%, and the gel is crosslinked polyacrylamide gel with the content of 2% and PBS buffer solution with the concentration of 0.1M.
The steps are as follows: the crosslinked polyacrylamide with the crosslinking degree of 0.1% is placed in a planetary ball mill for 400RPM and 3 hours to obtain solid particles with the particle size of 10-30 mu m.
The 0.1g of the cross-linked polyacrylamide solid particles are placed in 4.9g of PBS solution containing 5mg of dexamethasone sodium phosphate, the mixture is kept stand for 24 hours in the environment of 4 ℃ to obtain medicine-carrying gel, and the medicine-carrying gel is sterilized at the high temperature of 120 ℃ for 20min to obtain the gel injection D1 of the sustained release dexamethasone medicine.
The gel injection is shown in figure 1, is semitransparent, contains gel particles, has the particle diameter of 50-200 μm, can be smoothly injected into damaged knee joints of horse racing through a 1.6# needle of an injector, can continuously release dexamethasone sodium phosphate for 3 days, and has the effects of rapidly relieving swelling and promoting repair of damaged joints.
Example 2
The dexamethasone drug is dexamethasone, the content of the dexamethasone drug is 0.1%, the gel is cross-linked polyacrylamide gel, the content of the cross-linked polyacrylamide is 2%, and the rest is PBS buffer solution with the concentration of 0.1M.
The steps are as follows:
s1: placing crosslinked polyacrylamide with the crosslinking degree of 50% in a freezing crusher, and processing into solid particles with the particle size of 0.1-200 mu m under the freezing condition of minus 20 ℃;
s2: dissolving 5mg dexamethasone in 5ml of a mixed solution of ethanol and water, wherein the volume fraction of ethanol is 50%;
s3: placing 0.1g of the crosslinked polyacrylamide solid particles obtained in the step S1 into the solution obtained in the step S2, and standing at 37 ℃ for 72 hours to obtain a drug-loaded gel;
s4: and (3) freeze-drying the medicine-carrying gel obtained in the step (S3) to constant weight, then adding 4.9g of physiological saline, standing at room temperature for 72h to obtain the medicine-carrying gel, and sterilizing at a high temperature of 120 ℃ for 20min to obtain the gel injection D2 of the dexamethasone medicine.
The gel has particle diameter of 0.1-500 μm, and can be injected via 0.45# -1.6# various-size injection needles to release dexamethasone in controlled manner, as shown in figure 2, and can release dexamethasone rapidly in the first three days, and gradually slow down in 3-8 days. The injection can be injected into joint cavity for treating synovitis, and can rapidly eliminate swelling, gradually reduce drug release rate after three days, and gradually stop drug while stabilizing therapeutic effect, without causing adverse reactions such as osteoporosis, muscular atrophy, gastrointestinal dysfunction, etc.
Example 3
The dexamethasone drug is dexamethasone sodium phosphate, the content is 1%, the gel is cross-linked polyacrylamide gel, the content of cross-linked polyacrylamide is 2%, and the rest is PBS buffer solution with the concentration of 0.1M.
The steps are as follows:
s1: placing crosslinked polyacrylamide with the crosslinking degree of 20% in an ultrasonic crusher to be processed into solid particles with the particle size of 200-500 mu m;
s2: 50mg of dexamethasone phosphate was dissolved in 10mL of water;
s3: placing 0.1g of the crosslinked polyacrylamide solid particles obtained in the step S1 into the solution obtained in the step S2, and standing at 37 ℃ for 72 hours to obtain a drug-loaded gel;
s4: and (3) removing 7.1g of water from the medicine-carrying gel obtained in the step (S3) through Hong Gan at the temperature of 80 ℃, then adding 2g of zinc acetate solution with the concentration of 0.5M, standing for 24 hours at room temperature, and carrying out radiation sterilization to obtain the gel injection D3 of the dexamethasone medicine.
The gel particle size of the gel injection is 200-1000 μm, and the dexamethasone phosphate can be released for 30d by injecting through a 1.6# needle. The injection can be used for treating synovitis and osteoarthritis.
Example 4
The gel injection D4 for slowly releasing the dexamethasone medicine, wherein the dexamethasone medicine is dexamethasone acetate, the medicine content is 0.01%, the gel is crosslinked polyacrylamide gel, the crosslinked polyacrylamide content is 2%, the glycerol content is 10%, and the balance is water.
The steps are as follows:
s1: grinding crosslinked polyacrylamide with the crosslinking degree of 70% into solid particles with the particle size of 10-30 mu m;
s2: dissolving 0.5mg dexamethasone acetate phosphoric acid in 0.1g ethanol, and then adding 0.5g glycerol to obtain a drug-glycerol-ethanol mixed solution;
s3: placing 0.1g of the crosslinked polyacrylamide solid particles obtained in the step S1 into the mixed solution obtained in the step S2, and standing at room temperature for 12 hours to obtain mixed gel;
s4: and (3) drying the mixed gel obtained in the step (S3) in vacuum for 4 hours to remove ethanol, adding 4.4g of water for injection, magnetically stirring for 1 hour, and performing radiation sterilization to obtain the gel injection D4 of the dexamethasone drug.
The gel injection has gel particle diameter of 50-200 μm, can be injected as shown in figure 3, has antiinflammatory and lubricating effects, and can be used for joint lubrication and synovitis treatment.
Example 5
The dexamethasone drug is dexamethasone sodium phosphate, the content of the dexamethasone drug is 0.5%, the gel is crosslinked polyacrylamide gel, the content of the crosslinked polyacrylamide is 5%, and the balance is physiological saline.
The steps are as follows: crosslinked polyacrylamide with a degree of crosslinking of 0.1% was ground into microparticles.
The 0.25g of the crosslinked polyacrylamide particles are placed in 4.5g of physiological saline solution containing 25mg of dexamethasone sodium phosphate, the mixture is kept stand for 24 hours at the temperature of 4 ℃ to obtain medicine-carrying gel, and the medicine-carrying gel is sterilized at the temperature of 120 ℃ for 20min to obtain the gel injection D5 of the sustained release dexamethasone medicine.
The gel injection comprises gel particles with particle diameter of 0.5-1000 μm, can be injected, can rapidly eliminate inflammation, and can be used for repairing joint injury, lubricating joint, and treating arthritis and synovitis.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (6)

1. The gel injection for slowly releasing dexamethasone is characterized in that: the dexamethasone drug is entrapped in the gel particles, and the drug is partially soluble, and hydrogen bond interaction exists between dissolved drug molecules and gel network molecules, so that the drug can be slowly released;
the dexamethasone medicine is one or a combination of several of dexamethasone, dexamethasone sodium phosphate and dexamethasone acetate, and the medicine loading amount in the gel particles is 0.01% -1%;
the particle size of the gel particles is 0.5-1000 mu m, and the gel particles consist of crosslinked polyacrylamide, salt and water for injection, wherein the content of the crosslinked polyacrylamide is 0.01-5%; the salt content is 0.001% -5%, the crosslinking degree of the crosslinked polyacrylamide is 0.1% -99%, and the molecular weight of the used polyacrylamide is 1x10 4 -1x10 6 The molecular weight distribution coefficient is 1-5;
the preparation method of the gel injection for slowly releasing the dexamethasone drug comprises the following steps:
s1: processing the crosslinked polyacrylamide into micron particles;
s2: dissolving dexamethasone in one or more of water, ethanol and salt solution;
s3: mixing the liquid obtained in the step S2 with the powder obtained in the step S1 in proportion, and treating for 0.1-72h at 4-80 ℃ by adopting one or a combination of more of vibration, standing, stirring and ultrasound to obtain medicine carrying gel;
s4: and (3) removing or partially removing the solvent from the drug-loaded gel obtained in the step (S3) in a heating and/or vacuumizing and evaporation accelerating mode, adding a proper amount of water or salt solution in proportion, standing for 0.1-72h, and sterilizing to obtain the gel injection for slowly releasing the dexamethasone drug.
2. The dexamethasone drug slow release gel injection as defined in claim 1, wherein: the salt comprises one or a combination of several of sodium chloride, potassium chloride, zinc chloride, calcium chloride, magnesium chloride, zinc acetate, disodium hydrogen phosphate and potassium dihydrogen phosphate.
3. The dexamethasone drug slow release gel injection as defined in claim 1, wherein: can control the release of dexamethasone medicine, and the controlled release period of the medicine is 0.1h-30d.
4. The dexamethasone drug slow release gel injection as defined in claim 1, wherein: has injectability and can be injected by various types of syringes in clinical practice.
5. The gel injection of the sustained release dexamethasone drug according to claim 1, wherein the processing method of the crosslinked polyacrylamide into particles comprises one or a combination of a plurality of grinding, freezing and crushing and ultrasonic crushing.
6. Use of a gel injection of a sustained release dexamethasone drug according to any one of claims 1-5 in the preparation of a medicament for the treatment of synovitis and arthritis.
CN202110251929.1A 2021-03-08 2021-03-08 Gel injection of sustained release dexamethasone medicine, preparation method and application thereof Active CN112870155B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110251929.1A CN112870155B (en) 2021-03-08 2021-03-08 Gel injection of sustained release dexamethasone medicine, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110251929.1A CN112870155B (en) 2021-03-08 2021-03-08 Gel injection of sustained release dexamethasone medicine, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN112870155A CN112870155A (en) 2021-06-01
CN112870155B true CN112870155B (en) 2023-06-30

Family

ID=76053772

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110251929.1A Active CN112870155B (en) 2021-03-08 2021-03-08 Gel injection of sustained release dexamethasone medicine, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN112870155B (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828828A (en) * 1987-07-28 1989-05-09 Trager Seymour F Method of treating degenerative joint disease by injection of meth(acrylamide) (co)-polymers
EP2497468A1 (en) * 2011-03-11 2012-09-12 Contura A/S Polyacrylamide hydrogel for use in the treatment and/or prevention of joint swelling and/or bone oedema in a mammal suffering from arthritis
CN103059220B (en) * 2012-12-25 2016-01-13 卢来春 A kind of method preparing HPMA-dexamethasone polymkeric substance
ES2930433T3 (en) * 2013-03-05 2022-12-12 Univ Pittsburgh Commonwealth Sys Higher Education Thermosensitive hydrogel containing polymer microparticles for non-invasive ocular drug delivery
TWI845973B (en) * 2015-01-21 2024-06-21 美商桑紐爾製藥公司 Pharmaceutical formulation
BR112017016087A2 (en) * 2015-01-28 2018-03-27 Allergan Inc adipose joint cushion formulations and methods of use thereof
RS61571B1 (en) * 2016-03-31 2021-04-29 Contura Int A/S Polyacrylamide hydrogel for use in the prevention and/or treatment of synovitis in a mammal
CN106963725A (en) * 2017-04-19 2017-07-21 赵艳霞 A kind of dexamethasone nanogel and preparation method thereof

Also Published As

Publication number Publication date
CN112870155A (en) 2021-06-01

Similar Documents

Publication Publication Date Title
CN109528695B (en) Microneedle transdermal drug delivery patch for treating rheumatoid arthritis and preparation method thereof
CN101583366B (en) Radiosensitizers or anticancer chemotherapy sensitizers
Rudnik-Jansen et al. Prolonged inhibition of inflammation in osteoarthritis by triamcinolone acetonide released from a polyester amide microsphere platform
JP5622725B2 (en) Sustained delivery of exenatide and other polypeptides
US20130149318A1 (en) Painting the pia, arachnoid, and spinal cord parenchyma
AU2009262263B2 (en) Octreotide implant having a release agent
JP2012520297A (en) Products and methods for the treatment of vascular diseases
CN108926714B (en) High-molecular gel for delivering pharmacological active substances to bladder cancer in bladder perfusion targeted manner and preparation method of high-molecular gel
CN101536987A (en) Sodium alginate microballoon vein suppository containing hemangioma-resisting medicant, preparation method and application thereof
Tnibar Intra-articular 2.5% polyacrylamide hydrogel, a new concept in the medication of equine osteoarthritis: a review
EP3626256B1 (en) Compostion for the treatment of tissue lesions
Agiba Nutraceutical formulations containing glucosamine and chondroitin sulphate in the treatment of osteoarthritis: Emphasis on clinical efficacy and formulation challenges
CN112870155B (en) Gel injection of sustained release dexamethasone medicine, preparation method and application thereof
CN118697761A (en) Use of polidocanol in preparing a drug for treating lymphatic leakage
FR3066386A1 (en) PROCESS FOR PREPARING AN AQUEOUS GEL OF HYALURONIC ACID
CN104324032A (en) Triple compound microsphere vascular targeted embolization sustained-release preparation containing antituberculous drug as well as preparation method and application of preparation
US20140005199A1 (en) Implant for the controlled release of pharmaceutically active agents
CN102670611B (en) Vascular targeting embolism sustained release agent of triple compound microsphere for antituberculosis drug, preparation method and applications thereof
EP3389675A1 (en) Hyaluronic acid composition for penile injections
WO2014050912A1 (en) Liquid medicine having carbon dioxide dissolved therein, and therapeutic method using same
CN119235748A (en) Preparation method of sponge implant with rapid and long-term analgesic, anti-inflammatory, antipyretic and wound healing effects
Jiang et al. Local anesthetics effects of lidocaine-loaded chitosan nanoparticles in a rat model: An in vitro and in vivo study
TW201909923A (en) Thermosensitive biodegradable elastomer, and preparation method and use thereof capable of achieving the effects of prolonging the effect of hyaluronic acid and easy injection
CN117159453A (en) Injectable tofacitinib drug sustained-release gel particles and preparation method thereof
WO2021076076A1 (en) Cystitis solution comprising hyaluronic acid and polyethylene glycol and production method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant